James Cheek has abruptly left his position as CEO of a molecular testing company. The decision was made by mutual agreement.
This sudden change comes less than a year after Cheek’s appointment, adding a layer of complexity to the company’s leadership dynamics.
Immediate Departure
James Cheek, the Chief Executive of a molecular testing business, has left the company with immediate effect. The company announced in a statement this morning that his departure was by mutual agreement.
New Leadership
Dr Gino Miele has stepped in as the new CEO. Dr Miele has been with the company since 2011 and has held various roles including R&D Director and Chief Scientific Officer.
Dr Miele’s Background
Before joining the company, Dr Miele was an Associate Director at Wyeth and Pfizer. He has been instrumental in advancing the company’s pharmacogenomic testing capabilities and regulatory approvals.
Regulatory Achievements
Dr Miele played a key role in obtaining NICE approval for the Genedrive MT-RNR1 ID Kit and the Genedrive CYP2C19 ID Kit. Additionally, he secured clinical trial agreements in the US and achieved FDA breakthrough device designation.
Company’s Confidence
Gilham stated, “Gino has an unparalleled knowledge and understanding of the company’s products and commercial strategies.”
James Cheek’s Short Tenure
On his appointment, the company had praised Cheek’s experience with the NHS and expected valuable contributions to their commercial footprint.
Future Prospects
With CE-IVD and UKCA certifications, the company estimates the market potential to be worth over £100 million annually.
As the company moves forward under new leadership, Dr Miele’s extensive experience and previous contributions will be crucial.
The focus will now be on maintaining the momentum in pharmacogenomic testing and capitalising on new commercial opportunities.
